A5089038984- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Advanced Breast Cancer Therapies
- Plasma Diagnostics and Applications
- Ubiquitin and proteasome pathways
Epic Sciences (United States)
2023
Abstract Purpose: In men with metastatic castration-resistant prostate cancer (mCRPC), prostate-specific membrane antigen (PSMA)-targeted radioligand therapy has drastically improved clinical outcomes. A liquid biopsy characterizing PSMA expression could be useful in guiding optimal therapy. Experimental Design: We conducted a retrospective analysis of the prospective multicenter PROPHECY (Prospective CiRculating PrOstate Cancer Predictors HighEr Risk mCRPC StudY) trial (n = 118) treated...
<p>PSMA protein expression distribution from men with mCRPC at a single cell CTC level before (baseline, N= 97) and after (progression, 57) abiraterone or enzalutamide therapy.</p>
<p>The prevalence of PSMA and Cell Search CTC positivity (≥5) at baseline progression, as well the observed median optimal cutoffs for CTC.</p>
<p>Comparison of CTC enumeration and PSMA+ expression in 57 baseline paired progression samples from the PROPHECY study. All parameters (mean, median, range) were represent CTC/mL.</p>
<p>Percent PSMA expression positivity (PSMA+CTC x 100/Traditional CTC) across PSMA+ Neuroendocrine Phenotype (NE) - and NE+ baseline (A) progression (B) samples.</p>
<p>Waterfall plots depicting A) the proportion of men achieving a 50% or greater PSA decline from baseline, confirmed with subsequent value (confirmed PSA50) and B) best overall objective radiographic responses among response evaluable subjects at by RECIST 1.1 criteria.</p>
<p>Kaplan Meier plots depict the association between PSMA+ CTC enumeration and OS PFS. The associations of with overall survival (OS) progression-free (PFS) were explored using proportional hazard model. A) median in months for CTC=0 (reference), CTC+ PSMA-CTC, PSMA+CTC but heterogeneous (<100%), 100% (homogeneous), respectively, 25.7 (95% CI=19.8-NR), 24.5 CI=16.7-30.4),15.6 CI=14.4-20.7), 35.0 CI=16.9-NA). Univariate ratio (HR) was 1.3 CI=0.7-2.6), 2.0 CI=1.0-3.8) 0.7; 95% CI =...
<p>A. Overall Survival outcomes and B. Progression Free utilizing multivariate analysis for PSMA positive CTCs, adjusting on prior treatment, risk score, CTC enumeration, comparting 3 + groups with the reference group being 0.</p>
<p>CTC biomarker group incidence by PSMA optimal cutoff (AR-v7, chromosomal instability (CIN), and neuroendocrine (NE) at baseline (N=97) progression (N=57).</p>
<div>AbstractPurpose:<p>In men with metastatic castration-resistant prostate cancer (mCRPC), prostate-specific membrane antigen (PSMA)-targeted radioligand therapy has drastically improved clinical outcomes. A liquid biopsy characterizing PSMA expression could be useful in guiding optimal therapy.</p>Experimental Design:<p>We conducted a retrospective analysis of the prospective multicenter PROPHECY (Prospective CiRculating PrOstate Cancer Predictors HighEr Risk mCRPC...
<div>AbstractPurpose:<p>In men with metastatic castration-resistant prostate cancer (mCRPC), prostate-specific membrane antigen (PSMA)-targeted radioligand therapy has drastically improved clinical outcomes. A liquid biopsy characterizing PSMA expression could be useful in guiding optimal therapy.</p>Experimental Design:<p>We conducted a retrospective analysis of the prospective multicenter PROPHECY (Prospective CiRculating PrOstate Cancer Predictors HighEr Risk mCRPC...
<p>Comparison of CTC enumeration and PSMA+ expression in 57 baseline paired progression samples from the PROPHECY study. All parameters (mean, median, range) were represent CTC/mL.</p>
<p>Waterfall plots depicting A) the proportion of men achieving a 50% or greater PSA decline from baseline, confirmed with subsequent value (confirmed PSA50) and B) best overall objective radiographic responses among response evaluable subjects at by RECIST 1.1 criteria.</p>
<p>A. Overall Survival outcomes and B. Progression Free utilizing multivariate analysis for PSMA positive CTCs, adjusting on prior treatment, risk score, CTC enumeration, comparting 3 + groups with the reference group being 0.</p>
<p>CTC biomarker group incidence by PSMA optimal cutoff (AR-v7, chromosomal instability (CIN), and neuroendocrine (NE) at baseline (N=97) progression (N=57).</p>
<p>PSMA protein expression distribution from men with mCRPC at a single cell CTC level before (baseline, N= 97) and after (progression, 57) abiraterone or enzalutamide therapy.</p>
<p>Percent PSMA expression positivity (PSMA+CTC x 100/Traditional CTC) across PSMA+ Neuroendocrine Phenotype (NE) - and NE+ baseline (A) progression (B) samples.</p>
<p>Kaplan Meier plots depict the association between PSMA+ CTC enumeration and OS PFS. The associations of with overall survival (OS) progression-free (PFS) were explored using proportional hazard model. A) median in months for CTC=0 (reference), CTC+ PSMA-CTC, PSMA+CTC but heterogeneous (<100%), 100% (homogeneous), respectively, 25.7 (95% CI=19.8-NR), 24.5 CI=16.7-30.4),15.6 CI=14.4-20.7), 35.0 CI=16.9-NA). Univariate ratio (HR) was 1.3 CI=0.7-2.6), 2.0 CI=1.0-3.8) 0.7; 95% CI =...
<p>The prevalence of PSMA and Cell Search CTC positivity (≥5) at baseline progression, as well the observed median optimal cutoffs for CTC.</p>
<p>A. Overall Survival outcomes and B. Progression Free utilizing multivariate analysis for PSMA positive CTCs, adjusting on prior treatment, risk score, CTC enumeration, comparting 3 + groups with the reference group being 0.</p>
<p>PSMA protein expression distribution from men with mCRPC at a single cell CTC level before (baseline, N= 97) and after (progression, 57) abiraterone or enzalutamide therapy.</p>
<p>Kaplan Meier plots depict the association between PSMA+ CTC enumeration and OS PFS. The associations of with overall survival (OS) progression-free (PFS) were explored using proportional hazard model. A) median in months for CTC=0 (reference), CTC+ PSMA-CTC, PSMA+CTC but heterogeneous (<100%), 100% (homogeneous), respectively, 25.7 (95% CI=19.8-NR), 24.5 CI=16.7-30.4),15.6 CI=14.4-20.7), 35.0 CI=16.9-NA). Univariate ratio (HR) was 1.3 CI=0.7-2.6), 2.0 CI=1.0-3.8) 0.7; 95% CI =...
<p>CTC biomarker group incidence by PSMA optimal cutoff (AR-v7, chromosomal instability (CIN), and neuroendocrine (NE) at baseline (N=97) progression (N=57).</p>
<p>Comparison of CTC enumeration and PSMA+ expression in 57 baseline paired progression samples from the PROPHECY study. All parameters (mean, median, range) were represent CTC/mL.</p>
<p>The prevalence of PSMA and Cell Search CTC positivity (≥5) at baseline progression, as well the observed median optimal cutoffs for CTC.</p>